Compare STG & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STG | MDXH |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | China | Belgium |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.1M | 68.7M |
| IPO Year | 2017 | 2021 |
| Metric | STG | MDXH |
|---|---|---|
| Price | $2.98 | $0.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 23.4K | ★ 16.3M |
| Earning Date | 05-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | $1.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $0.40 |
| 52 Week High | $8.74 | $5.33 |
| Indicator | STG | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 41.34 | 51.94 |
| Support Level | $2.61 | $0.51 |
| Resistance Level | $3.64 | $1.13 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 40.91 | 0.00 |
Sunlands Technology Group operates in China's adult online education market and adult personal interest learning market through its online platforms. The Group has a deep understanding of the educational needs of its prospective students and offers solutions to help them achieve their goals. It provides online professional courses and educational content, including interest, professional skills, professional certification preparation courses, and degree- or diploma-oriented post-secondary courses. The Group adopts a counseling-oriented sales and marketing approach to offer education solutions based on students' backgrounds and goals, delivering adult online education and personal interest learning through extensive course and content offerings.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.